The US market for Hemostats and Sealants accelerated in Q418 driven by growth in fibrin sealants and thrombin hemostats, overcoming slow growth during the first half of the year.

The US market for Hemostats and Sealants accelerated with +9.3% YoY growth in Q418, continuing to build on its +7.9% YoY in Q318, with fibrin sealants and thrombin hemostats driving the increase. The US market grew +6.1% in FY18, overcoming slow growth during the first half of the year.

As reported in SmartTRAK Financial Dashboard, every manufacturer in the Hemostats and Sealants market, except Pfizer and CryoLife, experienced revenue growth in Q418. Leading the way was Baxter with +33.1% YoY growth as it made progress with its integration of the Mallinckrodt portfolio. Ethicon and Becton Dickinson (BD) both posted solid gains, with +8.7% YoY and +6.6% YoY growth, respectively...

SmartTRAK was cited as a source in a press release from Smith & Nephew entitled "Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc."

The US Surgical Matrices Market continued to advance in Q418, driven by a resurgence of Becton Dickinson in hernia matrices and continued growth of breast matrices.  The US market grew +9.7% in FY18.

SmartTRAK reports that the US Surgical Matrices market grew in both the Breast and Hernia Repair segments. SmartTRAK estimates the Breast segment grew again at +21.8% YoY growth to 35.2% share of the entire Surgical Matrices market. The Hernia Repair market continued its recovery up +4.8% YoY and 64.8% share of the US Surgical Matrices Market in Q418.  

Among the many topics covered in the Q418/FY18 Surgical Matrices Market Recap are:

FY18 showed solid gains in all segments, up +5.7% YoY, as antimicrobial devices take the lead.

Following the last fall's Advanced Wound Care meeting, SmartTRAK's Susan Paquette, VP Wound, reported on advances in negative pressure wound therapy (NPWT), fiber dressings and human dermal tissue and the latest research and company news, identifying what’s new and what’s next in the market for advanced wound care.

Doug Devens, SmartTRAK's Senior Analyst, Biosurgery wrote a fascinating article titled "Growth Amid Debate: Open vs Robotic Techniques for Inguinal Hernia Repair", in which he shines a light on issues and trends in robotic surgery and the market for inguinal hernia matrices.

SUTUREGARD is on a mission to close more wounds simply and safely

Company Overview

Founded in 2015 and based in Portland, Oregon, SUTUREGARD™ Medical, Inc. is a privately held medical device firm with patented technology that allows surgeons to perform simple closures of high-tension wounds through rapid intraoperative tissue expansion. For skin cancer surgeons (Mohs Surgeons), SUTUREGARD’s initial target market, the SUTUREGARD™ device allows closure of wounds using tissue expansion instead of relying on flaps, grafts, or second intent healing. This is particularly useful for scalp and lower leg closures. For some skin cancer surgeons, this will add greater efficiency to their day. For other skin cancer surgeons, this will retain closures in their practice that they would have otherwise sent to other specialists.

The Company founders — a Corvallis, Oregon-based skin cancer (Moh’s) surgeon and his Ph.D. nurse business partner — designed the SUTUREGARD device. The Company invested three years conducting bench research, pre-clinical studies, and customer discovery prior to completion of a successful human use study in 2018.

“SUTUREGARD Medical launched the SUTUREGARD device in November, 2018 at the Fundamentals of Mohs Surgery Conference and the product was enthusiastically received by surgeons.”   Dan Ladizinsky, MD, CEO of SUTUREGARD Medical.

Growth continues for another quarter as market leaders gain more share.

For Q318, according to BioMedGPS’ SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access Adjunct Products market grew +4.3% YoY.

Among the many topics covered in the Q318 Infection Prevention Market Recap are:

The US market for Hemostats and Sealants accelerated substantially in Q318 vs Q218

As reported in SmartTRAK’s Financial Dashboard, every manufacturer in the Hemostats and Sealants market, with the exception of Pfizer, saw revenue growth in Q318. Leading the way were Baxter, with its integration of the Mallinckrodt portfolio, as well as Ethicon and Integra, while Pfizer posted...

Among the many topics covered in the Q318 US Hemostats and Sealants Market Recap are:

All segments showing softness, lowest quarterly growth rate since 2015

For Q318, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics was up +3.0% YoY, with Acelity, also known as KCI, maintaining its leadership position with estimated Q318 revenues of...